Skip to content

Management

Anders Månsson

CEO since 2022

Born: 1967

Education: Bachelor of Science in Business & Economics from Lund University and an Executive MBA from Business School Lausanne.

Work experience: Several leading roles in global pharmaceutical companies, both in Sweden and abroad with experience from sales, marketing and business development. Anders has been CEO for smaller companies, such as RhoVac,and Amniotics and has had leading roles in among others LEO Pharma and Ferring and been industrial advisor to Ratos. He has also been Board member in several smaller biotech- and pharmaceutical companies.

Holdings: 0 shares, 0 warrants

lidds-jenni-bjornlfson-people

Jenni Björnulfson

CFO and Head of IR since 2021

Born: 1971

Education: Master’s degree in Finance and Managerial economics from Stockholm School of Economics and studies at the Karolinska Institute

Work experience: Extensive financial and industrial background working for many years within the health care sector. Previous positions include being CFO for Promore Pharma and Cinclus Pharma Holding. Prior to that Jenni worked as an equities analyst at ABG Sundal Collier and she has held corporate finance positions at Alfred Berg and Handelsbanken

Holdings: 0 shares, 35,000 warrants

lidds-matthew-lindon-people

Matthew Lindon

CSO since 2022

Born: 1973

Education: Bachelor of Science in Chemistry from the University of Leicester

Work experience: Strong background from the pharmaceutical sector with over 20 years’ experience of integrated drug discovery and development. Previous positions include Senior Director and Global Project Leader with a focus on drug discovery and early clinical development at GSK, and most recently at AstraZeneca where he was leading a portfolio of drug discovery and development projects in the Respiratory & Immunology therapy area.

Holdings: 0 shares, 0 warrants

Annette Møldrup

CBDO since 2022

Born: 1961

Education: Ph.D. in Biochemistry from University of Copenhagen.

Work experience: Over twenty years of experience from business development, focusing on in-licensing and out-licensing agreements at Novo Nordisk and Ferring.

Holdings: 0 shares, 0 warrants